These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33571286)

  • 1. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.
    Plummer EL; Bradshaw CS; Doyle M; Fairley CK; Murray GL; Bateson D; Masson L; Slifirski J; Tachedjian G; Vodstrcil LA
    PLoS One; 2021; 16(2):e0246953. PubMed ID: 33571286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of bacterial vaginosis with high dosage metronidazole and lactic acid].
    Andreeva P; Slavchev B; Kovachev S; Nacheva A; Vacheva R
    Akush Ginekol (Sofiia); 2002; 41(5):36-9. PubMed ID: 12440337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics.
    Ling Z; Liu X; Chen W; Luo Y; Yuan L; Xia Y; Nelson KE; Huang S; Zhang S; Wang Y; Yuan J; Li L; Xiang C
    Microb Ecol; 2013 Apr; 65(3):773-80. PubMed ID: 23250116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.
    Recine N; Palma E; Domenici L; Giorgini M; Imperiale L; Sassu C; Musella A; Marchetti C; Muzii L; Benedetti Panici P
    Arch Gynecol Obstet; 2016 Jan; 293(1):101-107. PubMed ID: 26142892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome.
    Verstraelen H; Vervaet C; Remon JP
    PLoS One; 2016; 11(4):e0153441. PubMed ID: 27093291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial.
    Anstey Watkins J; Ross JDC; Thandi S; Brittain C; Kai J; Griffiths F
    PLoS One; 2019; 14(11):e0224964. PubMed ID: 31730666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota.
    Delgado-Diaz DJ; Tyssen D; Hayward JA; Gugasyan R; Hearps AC; Tachedjian G
    Front Cell Infect Microbiol; 2019; 9():446. PubMed ID: 31998660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal microbiome.
    Buchta V
    Ceska Gynekol; 2018; 83(5):371-379. PubMed ID: 30848142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Lactobacillus crispatus isolates from Lactobacillus-dominated vaginal microbiomes with isolates from microbiomes containing bacterial vaginosis-associated bacteria.
    Abdelmaksoud AA; Koparde VN; Sheth NU; Serrano MG; Glascock AL; Fettweis JM; Strauss JF; Buck GA; Jefferson KK
    Microbiology (Reading); 2016 Mar; 162(3):466-475. PubMed ID: 26747455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis.
    Gottschick C; Deng ZL; Vital M; Masur C; Abels C; Pieper DH; Rohde M; Mendling W; Wagner-Döbler I
    Microbiome; 2017 Sep; 5(1):119. PubMed ID: 28903767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Molecule Approach to 16S rRNA for Vaginal Microbiome Signatures in Response to Metronidazole Treatment.
    Qin H; Jiao J; A D; Hua M; Han K; Du H; Wang Z; Li J; Zhang D; Xiao B; Chen C
    Microbiol Spectr; 2023 Jun; 11(3):e0170622. PubMed ID: 37199621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs.
    van de Wijgert J; Verwijs MC
    BJOG; 2020 Jan; 127(2):287-299. PubMed ID: 31299136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment.
    Bahamondes MV; Portugal PM; Brolazo EM; Simões JA; Bahamondes L
    Rev Assoc Med Bras (1992); 2011; 57(4):415-20. PubMed ID: 21876923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lactic acid production by probiotic Lactobacillus species in vaginal health.
    Tachedjian G; Aldunate M; Bradshaw CS; Cone RA
    Res Microbiol; 2017; 168(9-10):782-792. PubMed ID: 28435139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronidazole with Lactacyd vaginal gel in bacterial vaginosis.
    Decena DC; Co JT; Manalastas RM; Palaypayon EP; Padolina CS; Sison JM; Dancel LA; Lelis MA
    J Obstet Gynaecol Res; 2006 Apr; 32(2):243-51. PubMed ID: 16594932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.
    Armstrong-Buisseret L; Brittain C; David M; Dean G; Griffiths F; Hepburn T; Jackson L; Kai J; Montgomery A; Roberts T; Thandi S; Ross JDC
    Trials; 2019 Nov; 20(1):648. PubMed ID: 31775859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.
    Happel AU; Singh R; Mitchev N; Mlisana K; Jaspan HB; Barnabas SL; Passmore JS
    BMC Infect Dis; 2020 Jul; 20(1):491. PubMed ID: 32650729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis.
    Deng ZL; Gottschick C; Bhuju S; Masur C; Abels C; Wagner-Döbler I
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile.
    Armstrong E; Hemmerling A; Miller S; Huibner S; Kulikova M; Liu R; Crawford E; Castañeda GR; Coburn B; Cohen CR; Kaul R
    Microbiol Spectr; 2024 Aug; 12(8):e0350123. PubMed ID: 38912808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis.
    Plummer EL; Vodstrcil LA; Doyle M; Danielewski JA; Murray GL; Fehler G; Fairley CK; Bulach DM; Garland SM; Chow EPF; Hocking JS; Bradshaw CS
    mBio; 2021 Oct; 12(5):e0232321. PubMed ID: 34663095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.